Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 4, 2011, Pages 1433-1438

  Ren, Dongmei ^a,b   Villeneuve, Nicole F ^a   Jiang, Tao ^a   Wu, Tongde ^a   Lau, Alexandria ^a   Toppin, Henry A ^a   Zhang, Donna D ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antioxidant response; Chemosensitization; Natural compounds; Reactive oxygen species

Indexed keywords

BRUSATOL; CISPLATIN; GLUTATHIONE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR GROWTH; TUMOR XENOGRAFT; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; GLUTATHIONE; HELA CELLS; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SPACE; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NF-E2-RELATED FACTOR 2; QUASSINS; SIGNAL TRANSDUCTION; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952122321     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1014275108     Document Type: Article

References (47)

1. Schiller JH (2001) Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61(Suppl 1):3-13.
2. Zhang DD (2006) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 38:769-789.
3. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89-116.
4. Jeong WS, Jun M, Kong AN (2006) Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal 8:99-106. (Pubitemid 43324535)
5. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24:10941-10953. (Pubitemid 39603148)
6. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA (2004) The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: Oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24:8477-8486. (Pubitemid 39245070)
7. Furukawa M, Xiong Y (2005) BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 25:162-171. (Pubitemid 40039808)
8. Kobayashi A, et al. (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24:7130-7139. (Pubitemid 39014439)
9. Hayes JD, Kelleher MO, Eggleston IM (2008) The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Nutr 47(Suppl 2):73-88. (Pubitemid 351644183)
10. Kong AN, et al. (2001) Signal transduction events elicited by cancer prevention compounds. Mutat Res 480-481:231-241.
11. Itoh K, Mimura J, Yamamoto M (2010) Discovery of the negative regulator of Nrf2, Keap1: A historical overview. Antioxid Redox Signal 13:1665-1678.
12. Dinkova-Kostova AT, et al. (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99:11908-11913. (Pubitemid 34994497)
13. Ramos-Gomez M, et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98:3410-3415. (Pubitemid 32220859)
14. Khor TO, et al. (2008) Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila) 1:187-191.
15. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD (2008) Dual roles of Nrf2 in cancer. Pharmacol Res 58:262-270.
16. Hayes JD, McMahon M (2009) NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem Sci 34:176-188.
17. Hayes JD, McMahon M (2006) The double-edged sword of Nrf2: Subversion of redox homeostasis during the evolution of cancer. Mol Cell 21:732-734. (Pubitemid 43376123)
18. Kensler TW, Wakabayashi N (2010) Nrf2: Friend or foe for chemoprevention? Carcinogenesis 31:90-99.
19. Padmanabhan B, et al. (2006) Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21:689-700. (Pubitemid 43290735)
20. Singh A, et al. (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3:e420.
21. Ohta T, et al. (2008) Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68:1303-1309. (Pubitemid 351346836)
22. Solis LM, et al. (2010) Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16:3743-3753.
23. Stacy DR, et al. (2006) Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 28:813-818. (Pubitemid 44320535)
24. Shibata T, et al. (2008) Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135(4):1358-1368, 1368.e1-4.
25. Shibata T, et al. (2008) Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105:13568-13573.
26. Kim YR, et al. (2010) Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220:446-451.
27. Jiang T, et al. (2010) High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 70:5486-5496.
28. Wang XJ, et al. (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29:1235-1243.
29. Zhang P, et al. (2010) Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 9:336-346.
30. Homma S, et al. (2009) Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15:3423-3432.
31. Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK (2008) Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance. Cancer Lett 260:96-108.
32. Hong YB, et al. (2010) Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas 39:463-472.
33. Singh A, et al. (2008) RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68:7975-7984.
34. Shim GS, Manandhar S, Shin DH, Kim TH, Kwak MK (2009) Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med 47:1619-1631.
35. Kim SK, et al. (2008) Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med 45:537-546.
36. Du Y, et al. (2008) Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response. Environ Health Perspect 116:1154-1161.
37. Cuendet M, Gills JJ, Pezzuto JM (2004) Brusatol-induced HL-60 cell differentiation involves NF-kappaB activation. Cancer Lett 206:43-50. (Pubitemid 38281252)
38. Zhang DD, et al. (2005) Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J Biol Chem 280:30091-30099. (Pubitemid 41216185)
39. Hall IH, et al. (1979) Antitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells. J Pharm Sci 68:883-887. (Pubitemid 9224264)
40. Eigebaly SA, et al. (1979) Antitumor agents. XXXV: Effects of brusatol, bruceoside A, and bruceantin on P-388 lymphocytic leukemia cell respiration. J Pharm Sci 68: 887-890. (Pubitemid 9224265)
41. Willingham W, Jr., et al. (1981) Mechanism of eukaryotic protein synthesis inhibition by brusatol. Biochim Biophys Acta 654:169-174.
42. Liou YF, Hall IH, Okano M, Lee KH, Chaney SG (1982) Antitumor agents XLVIII: Structure-activity relationships of quassinoids as in vitro protein synthesis inhibitors of P-388 lymphocytic leukemia tumor cell metabolism. J Pharm Sci 71:430-435. (Pubitemid 12123805)
43. Hall IH, Liou YF, Lee KH, Chaney SG, Willingham W, Jr. (1983) Antitumor agents LIX: Effects of quassinoids on protein synthesis of a number of murine tumors and normal cells. J Pharm Sci 72:626-630. (Pubitemid 13062788)
44. Lee KH, Okano M, Hall IH, Brent DA, Soltmann B (1982) Antitumor agents XLV: Bisbrusatolyl and brusatolyl esters and related compounds as novel potent antileukemic agents. J Pharm Sci 71:338-345. (Pubitemid 12083734)
45. Mata-Greenwood E, et al. (2001) Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a] anthracene-induced preneoplastic lesion formation in mouse mammary organ culture. J Nat Prod 64:1509-1513.
46. Mata-Greenwood E, et al. (2002) Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. Leukemia 16:2275-2284. (Pubitemid 35331844)
47. Chen W, et al. (2009) Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 34:663-673.